title: Pergolide-associated valvular heart disease.
abstract: Pergolide is an ergot derivative dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. Ergot derivatives are known to be associated with fibrotic conditions, including a carcinoid-like, fibrotic, valvular heart disease (VHD). Recently, pergolide was identified in association with the development of VHD. This article includes a summary of the literature published on pergolide-associated VHD, a description of the potential mechanisms of drug-induced VHD, and the clinical implications for the management of patients taking pergolide.
authors.affiliation: Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32256, USA.
authors.forename: E Andrew
authors.initials: EA
authors.lastname: Waller
authors.forename: Joseph
authors.initials: J
authors.lastname: Kaplan
mesh_terms: D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D010479:Pergolide / Q000009:adverse effects*; D015995:Prevalence; D011658:Pulmonary Fibrosis / Q000139:chemically induced; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced
chemical_list: D018491:Dopamine Agonists; D010479:Pergolide